The FDA approved adaptive deep brain stimulation (DBS) technology (BrainSense adaptive DBS and BrainSense electrode ...

The "U.S. Deep Brain Stimulation In Parkinson's Disease Market Size, Share & Trends Analysis Report By Product ...

BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients with Parkinson’s ...

The BrainSense adaptive deep brain stimulation system personalizes therapy by dynamically adjusting stimulation based on real ...

Researchers from Carnegie Mellon University and Allegheny Health Network have developed a new method for deep brain ...

Medtronic's FDA-approved BrainSense Adaptive DBS system revolutionizes Parkinson's therapy with real-time adjustments for ...

Brain scientists have developed DeepFocus, a novel technique to reach the deep brain without invasive surgery to treat mental ...

For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug ...

Carnegie Mellon researchers developed "DeepFocus," a new method for brain stimulation that combines transnasal and transcranial electrical stimulation for minimally invasive targeting of deep brain ...

Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the ...

Side effects of deep brain stimulation in people to treat Parkinson's may include impulsivity and depression. Biomedical ...

The FDA has approved adaptive deep brain stimulation (aDBS) for Parkinson’s disease, marking a breakthrough in treatment. This therapy continuously monitors brain activity and delivers targeted ...